displaying 1 - 5 records in total 5
    records per page

    Comparative analysis of immune-associated genes in COVID-19, cardiomyopathy HP cardiomyopathy MESHD and venous thromboembolism MESHD thromboembolism HP

    Authors: Grant E Castaneda; Abby C Lee; Wei Tse Li; Chengyu Chen; Jaideep Chakladar; Eric Chang; Weg Ongkeko; Xiaojian Liu; Wei Gao; Renli Zhang; Qiru Su; Andrew Azman; Justin Lessler; Xuan Zou; Wenfeng Gong; Brenda Clemente; Jerel Vega; Scott Roberts; Jose A. Gonzalez; Marciano Sablad; Rodrigo Yelin; Wendy Taylor; Kiyoshi Tachikawa; Suezanne Parker; Priya Karmali; Jared Davis; Sean M Sullivan; Steve G. Hughes; Pad Chivukula; Eng Eong Ooi

    doi:10.1101/2020.08.28.20184234 Date: 2020-09-02 Source: medRxiv

    As of 28 August 2020, there have been 5.88 million Coronavirus Disease MESHD 2019 (COVID-19) cases and 181,000 COVID-19 related deaths in the United States alone. Given the lack of an effective pharmaceutical treatment for COVID-19, the high contagiousness of the disease and its varied clinical outcomes, identifying patients at risk of progressing to severe disease is crucial for the allocation of valuable healthcare resources during this pandemic. Current research has shown that there is a higher prevalence SERO of cardiovascular comorbidities amongst patients with severe COVID-19 or COVID-19-related deaths, but the link between cardiovascular disease MESHD and poorer prognosis is poorly understood. We believe that pre-existing immune dysregulation HP that accompanies cardiovascular disease MESHD predisposes patients to a harmful inflammatory immune response, leading to their higher risk of severe disease. Thus, in this project, we aim to characterize immune dysregulation HP dysregulation MESHD in patients with cardiomyopathy HP cardiomyopathy MESHD, venous thromboembolism MESHD thromboembolism HP and COVID-19 patients by looking at immune-associated gene dysregulation, immune HP infiltration and dysregulated immunological pathways and gene signatures.

    Epidemiology of Venous Thromboembolism MESHD Thromboembolism HP in SARS- CoV-2 Infected MESHD Patients: A Systematic Review and Meta-Analysis

    Authors: Souvik Maitra; Dalim Kumar Baidya; Sulagna Bhattacharjee; Rahul Kumar Anand; Bikash Ranjan Ray; A. Christine Argento; Michelle H. Prickett; - NU COVID Investigators; Richard G. Wunderink; Sean B. Smith; Samira Mubareka; Allison McGeer; Adrienne K Chan; Anne-Claude Gingras; Tania H Watts; Mario Ostrowski; Elisabet Leiva; Albert Ariza-Sole; Paolo D Dallaglio; Maria Quero; Antonio Soriano; Alberto Pasqualetto; Maylin Koo; Virginia Esteve; Arnau Antoli; Rafael Moreno; Sergi Yun; Pau Cerda; Mariona Llaberia; Francesc Formiga; Marta Fanlo; Abelardo Montero; David Chivite; Olga Capdevila; Ferran Bolao; Xavier Pinto; Josep Llop; Antoni Sabate; Jordi Guardiola; Josep M Cruzado; Josep Comin-Colet; Salud Santos; Ramon Jodar; Xavier Corbella

    doi:10.1101/2020.08.28.20184028 Date: 2020-09-01 Source: medRxiv

    Early reports from China and Europe indicated that incidence of venous thromboembolism MESHD thromboembolism HP in COVID-19 patients may be high. In this meta-analysis of observational studies was designed to know worldwide prevalence SERO of thromboembolic MESHD events in COVID-19 patients. Primary outcome of our review was to assess the proportion of patients with VTE MESHD. Secondary outcomes were to assess the proportion of patients with DVT and proportion of patients with PE. Random effect meta-analysis model with restricted maximum likelihood estimator was used for all analysis. Pooled proportion with 95% confidence interval (95% CI) and heterogeneity (I2) was reported for all outcomes. Data of 5426 patients from n=19 articles were included in this systematic review and meta-analysis. Incidence of VTE MESHD (95% CI), PE (95% CI) and DVT (95% CI) was 23 (10- 36) %, 12 (6- 17) % and 15 (8- 23) %. We have found a high but incidence of thromboembolic MESHD events in COVID-19 patients. Further well-designed studies are required in this area to identify true incidence and risk factors of it.

    Prevalence SERO of Venous Thromboembolism HP in Critically-ill COVID-19 Patients: Systematic Review and Meta-analysis

    Authors: Mouhand F.H. Mohamed; Shaikha D. Al-Shokri; Khaled M. Shunnar; Sara F. Mohamed; Mostafa S. Najim; Shahd I. Ibrahim; Hazem Elewa; Khalid M. Dousa; Lina O. Abdalla; Ahmed El-Bardissy; Mohamed Nabil Elshafei; Ibrahim Y. Abubeker; Mohammed Danjuma; Mohamed A Yassin; Sharif A Ismail; Chengmin Shi; Zhenglin Du; Yadong Zhang; Chuandong Liu; Rujiao Li; Jingyao Zeng; Lili Hao; Shuai Jiang; Hua Chen; Dali Han; Jingfa Xiao; Zhang Zhang; Wenming Zhao; Yongbiao Xue; Yiming Bao; Valerie Mioulet; Joseph Newman; Amin S Asfor; Alison Burman; Sylvia Crossley; John Hammond; Elma Tchilian; Bryan Charleston; Dalan Bailey; Tobias J Tuthill; Simon Graham; Tomas Malinauskas; Jiandong Huo; Julia Tree; Karen Buttigieg; Ray Owens; Miles Carroll; Rod Daniels; John McCauley; Kuan-Ying A Huang; Mark Howarth; Alain Townsend

    doi:10.1101/2020.08.24.20175745 Date: 2020-08-29 Source: medRxiv

    Background: Recent studies revealed a high prevalence SERO of venous thromboembolism HP (VTE) events in coronavirus disease 2019 (COVID-19) patients, especially in those who are critically ill. Available studies report varying prevalence SERO rates. Hence, the exact prevalence SERO remains uncertain. Moreover, there is an ongoing debate regarding the appropriate dosage of thromboprophylaxis. Methods: We performed a systematic review and proportion meta-analysis following PRISMA guidelines. We searched PubMed and EMBASE for studies exploring the prevalence SERO of VTE in critically ill COVID-19 patients till 22/07/2020. We pooled the proportion of VTE. Additionally, in a subgroup analysis, we pooled VTE events detected by systematic screening. Finally, we compared the odds of VTE in patients on prophylactic compared to therapeutic anticoagulation. Results: The review comprised of 24 studies and over 2500 patients. The pooled proportion of VTE prevalence SERO was 0.31 (95% CI 0.24, 0.39 I2 94%), of VTE utilizing systematic screening was 0.48 (95% CI 0.33, 0.63 I2 91%), of deep-venous-thrombosis HP was 0.23 (95% CI 0.14, 0.32 I2 96%), of pulmonary embolism HP was 0.14 (95% CI 0.09, 0.20 I2 90%). In a subgroup of studies, utilizing systematic screening, VTE risk increased significantly with prophylactic, compared to therapeutic anticoagulation (OR 5.45; 95% CI 1.90, 15.57 I2 0%). Discussion: Our review revealed a high prevalence SERO of VTE in critically ill COVID-19 patients. Almost 50% of patients had VTE detected by systematic screening. Higher thromboprophylaxis dosages seem to reduce VTE burden in this patient's cohort compared to standard prophylactic anticoagulation; ongoing randomized controlled trials will further confirm this.

    High Incidence of Venous Thromboembolism MESHD Thromboembolism HP in Patients with Coronavirus Disease MESHD 2019: A Call for Improved Awareness and Prevention

    Authors: Yun-xia Zhang; Meng Zhang; Yimin Wang; Wei Qin; Zhu Zhang; Chenghong Li; Zhenguo Zhai

    doi:10.21203/rs.3.rs-60522/v1 Date: 2020-08-16 Source: ResearchSquare

    Background: An increased risk of venous thromboembolism MESHD thromboembolism HP ( VTE MESHD) in patients with coronavirus disease MESHD 2019 (COVID-19) has been reported. We performed a meta-analysis to evaluate the prevalence SERO of VTE MESHD in COVID-19 patients.Methods: The PubMed and Embase databases were searched for studies reporting VTE MESHD in COVID-19 patients up to June 27, 2020. The selected studies were predefined into the “suspected screening group” and the “routine screening group.” The VTE MESHD prevalence SERO was calculated using random-effect models.Results: We selected 20 studies including a total of 2763 COVID-19 patients. In 2203 COVID-19 patients from the suspected screening group, the pool VTE MESHD incidence was 15.2% (95% confidence interval [CI]: 10.5–21.6%). In 560 COVID-19 patients from the routine screening group, the VTE MESHD prevalence SERO was 40.8% (95% CI: 20.6–64.7%). Furthermore, the VTE MESHD incidence of critically ill COVID-19 patients from the two groups was 19.6% and 61.4%, respectively, which indicates that critically ill COVID-19 patients were more susceptible to VTE MESHD.Conclusions: A high incidence of VTE MESHD was observed in COVID-19 patients, especially in severe cases. The incidence of VTE MESHD in COVID-19 patients from the routine screening group was higher than that in patients from the suspected screening group. This indicates that a lower threshold of suspicion to perform VTE MESHD imaging tests may be reasonable and there is an urgent need to adapt a regular screening strategy for VTE MESHD.

    High Incidence of Venous Thrombosis HP Venous Thrombosis MESHD in Patients with Moderate to Severe COVID-19

    Authors: Oleg B Kerbikov; Pavel Yu Orekhov; Ekaterina N Borskaya; Natalia S Nosenko

    doi:10.1101/2020.06.12.20129536 Date: 2020-06-14 Source: medRxiv

    COVID-19 predisposes to venous thromboembolism MESHD thromboembolism HP and there are multiple data regarding high incidence of venous thrombosis HP venous thrombosis MESHD in critical COVID-19 patients, however reports on this complication in less severe patients are not widely available. The aim of this study was to investigate the incidence of deep-vein thrombosis MESHD ( DVT MESHD) in patients with moderate to severe COVID-19 and to assess the prevalence SERO of DVT MESHD with lung computerized tomography (lung CT) exams, clinical information and lab data. This study examined 75 consecutive patients with moderate to severe COVID-19, with specific exclusions. METHODS Almost all patients (pts) admitted to our hospital in the first half of May underwent comprehensive vein ultrasonography. 75 pts ( aged TRANS 27-92 y, median - 63 y, 36 males TRANS and 39 females TRANS) with moderate to severe COVID-19 were included in our study. RESULTS Spontaneous echo contrast (decreased blood SERO velocity and blood SERO stasis) was detected in common femoral veins in 53 pts (70.7%). DVT MESHD was found in 15 pts (20%). The vast majority of those with DVT MESHD (13 pts, 86.7%) had thrombi only in calf veins and ileofemoral thrombosis MESHD was detected in 2 pts with DVT MESHD (13.3%). There was no significant observed difference between DVT MESHD and non- DVT MESHD patients with respect to age TRANS, underlying diseases, lung CT scores and SpaO2 at admission. There was also no significant observed difference between DVT MESHD and non- DVT MESHD patients with respect to both "time from symptoms onset TRANS to admission" and with respect to the majority of lab data. However, a significant difference was observed in D-dimer level (1.87 +/- 1.62 vs 0.51 +/- 0,4 mcg/mL p<0.0001) and C-reactive protein (116.9 +/- 83,6 and 65.1 +/- 64.98 mg/L, p = 0.014) for patients with DVT MESHD and patients without DVT MESHD respectably (Receiver operating characteristics (ROC) curve analysis revealed that the level of D-dimer >/= 0.69 mcg/mL is the predictor of DVT MESHD with a sensitivity SERO of 76.9%, a specificity of 77.6%, p < 0.001 (AUC area under curve = 0.7944). Logistic regression confirmed that D-dimer is an independent predictor of DVT MESHD and patients with D-dimer >/= 0.69 mcg/mL have odds ratio (OR) of developing DVT MESHD = 5.1 (confidence interval [CI] 1.9 - 13.5)). CONCLUSION Patients with moderate to severe COVID-19 show high incidence of DVT MESHD, indicating that moderate to severe COVID-19 patients may require an early administration of anticoagulation therapy as part of their treatment. Such therapy may be continued after hospital discharge. Based on these findings, these patients may also require a follow-up with vein ultrasonography after recovery to rule out DVT MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.